Hope, hype, and high costs: Navigating glucagon-like Peptide-1 based therapy initiation among young adults.
GLP-1 research peptides are getting a lot of attention, especially among young adults chasing results in weight management. A new qualitative study from Florida International University breaks down what’s really driving this interest—and what’s getting in the way.
Obes Pillars
by Das Gupta S, Loubeau JK, Priyanka AS et al.
“Hope, hype, and high costs: Navigating glucagon-like Peptide-1 based therapy initiation among young adults. Das Gupta S(1), Loubeau JK(1), Priyanka AS(2), Cabrera Tineo YA(3), Diaz-Martinez J(4)(5), Hospital MM(6), Sanchez M(1)(3), Agarwal R(1)(5). Author information: (1)Department of Health Promotion and Disease Prevention, Robert Stempel College of Public Health and Social Work, Florida International University, 11200 SW 8th Street, Miami, FL, 33199, USA. (2)Department of Epidemiology, Robert Stempel College of Public Health and Social Work, Florida International University, 11200 SW 8th Street, Miami, FL, 33199, USA. (3)Center for Research on US Latino HIV/AIDS and Drug Abuse (CRUSADA), Robert Stempel College of Public Health and Social Work, Florida International University, 11200 SW 8th Street, Miami, FL, 33199, USA. (4)Department of Dietetics and Nutrition, Robert Stempel College of Public Health and Social Work, Florida International University, 11200 SW 8th Street, Miami, FL, 33199, USA. (5)Community Based Research Institute, Florida International University, 11200 SW 8th Street, Miami, FL, 33199, USA. (6)Department of Biostatistics, Robert Stempel College of Public Health and Social Work, Florida International University, 11200 SW 8th Street, Miami, FL, 33199, USA. BACKGROUND: Glucagon-like peptide-1 (GLP-1)-based therapies have emerged as a major option for weight management, with prescribing among young adults increasing nearly sixfold between 2020 and 2023 in the United States. Despite this growth, little is known about how young adults decide to initiate GLP-1 therapy, navigate access, and manage treatment costs. This study examined individual, social, financial, and structural influences shaping GLP-1 initiation for weight management among young adults. METHODS: This was a qualitative interview study that employed a semi-structured interview design utilizing a hybrid inductive-deductive thematic analysis framework guided by Andersen's Behavioral Model of Health Services Use. We recruited 25 young adults aged 18-30 years from the South Florida community who were currently using or had used GLP-1-based therapy for weight management within the preceding 12 months. Transcripts were coded deductively based on constructs from Andersen's model and inductively from themes identified directly from participant narratives. RESULTS: Participants had a mean age of 22 years; 20 (80%) were female and 19 (76%) identified as Hispanic or Latino. Four themes were identified: (1) motivations and expectations for initiation, including health needs, appearance-related goals, and social media-shaped expectations; (2) social and clinical pathways to GLP-1 introduction, particularly family networks and social media; (3) navigation of access pathways ranging from conventional clinical care to medical spas, telehealth, and unregulated self-procurement; and (4) financial barriers characterized by out-of-pocket costs and insurance exclusions that contributed to informal procurement. CONCLUSIONS: Within this sample, GLP-1 initiation among young adults was shaped by intersecting health needs, social influences, access structures, and financial constraints rather than by clinical considerations alone. Findings highlight that healthcare systems, policymakers, and public health practitioners must prioritize clinically appropriate access, reliable medication sourcing, and consistent clinical oversight to promote equity and safety among young adults. © 2026 The Authors. Published by Elsevier Inc. on behalf of Obesity Medicine Association. PMCID: PMC13653475 Conflict of interest statement: The authors declare no competing interests.”
It’s not just about the science. The research team interviewed 25 young adults, average age 22, who had started GLP-1-based therapy in the last year. Most were women, and a majority identified as Hispanic or Latino. The motivations? It’s a mix. Health goals are in the picture, but so are appearance, social media hype, and family influence. The “why” behind GLP-1 use is multi-layered.
Key takeaway: The path to starting GLP-1 isn’t always a straight line through a doctor’s office. Sure, some went the clinical route, but others found their compounds at medical spas, via telehealth, or even through less regulated sources. Social networks and Instagram are shaping decisions as much as any white coat.
But access isn’t the only hurdle. The cost of GLP-1 compounds is pushing some young adults to look outside traditional channels. Insurance barriers mean more people are paying out of pocket or seeking informal supply routes. This highlights the need for reliable information and better sourcing options, which you can find in our vendor directory.
Why does this matter for the research community? If you’re investigating GLP-1 or similar peptides, understanding the real-world context around access, motivation, and sourcing is crucial. There’s a lot more than just the molecule at play.
Curious about what’s driving peptide research and adoption? Check our peptide research index for more insights. The next big breakthrough might come from understanding not just the peptide, but how and why people are using it.
Related Reading
Periocular surgery risk after glucagon-like peptide-1 receptor agonist therapy for type 2 diabetes.
News · OMICSOral Versus Injectable Incretin-Based Anti-Obesity Therapies: An Integrated Computational and Evidence-Based Comparison of Orforglipron, Semaglutide, and Tirzepatide.
News · Cell Rep MedGut-derived glucagon-like peptides attenuate T cell-induced intestinal injury.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.